Piper Sandler Initiates Coverage of Revolution Medicines (RVMD) with an Overweight Rating

Revolution Medicines, Inc. (NASDAQ:RVMD) is one of the most promising future stocks according to Wall Street analysts. On August 18, Piper Sandler initiated coverage of Revolution Medicines, Inc. (NASDAQ:RVMD) with an Overweight rating and a $75 price target.

Revolution Medicines, Inc. (NASDAQ:RVMD) reported its fiscal Q2 2025 results on August 6, reporting strong execution of two ongoing Phase 3 trials of daraxonrasib.

Management reported that the company is winding down enrollment in the US for RASolute 302 and anticipates the completion of the enrollment of the trial this year.

Revolution Medicines, Inc. (NASDAQ:RVMD) also reported that the FDA Breakthrough Therapy Designations were granted for two RAS(ON) inhibitors, daraxonrasib and elironrasib.

Revolution Medicines, Inc. (NASDAQ:RVMD) is a clinical-stage precision oncology company that develops novel targeted therapies. It discovers and develops cancer treatments through novel combination and monotherapy treatment regimens that enhance clinical benefits.

While we acknowledge the potential of RVMD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.